The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer

類似資料

• Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
  著者:: Zhuang, Xibin, 等
  出版事項: (2019)
• Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
  著者:: Li, Xuefei, 等
  出版事項: (2016)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  著者:: Jia, Yijun, 等
  出版事項: (2020)
• Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
  著者:: Zhao, Chao, 等
  出版事項: (2020)
• Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
  著者:: Juan Zhou, 等
  出版事項: (2019-04-01)